Research News and Research

RSS

An unexpected ally for health reform: The restaurant industry

"While many small businesses are fighting to block passage of health care reform, restaurant owners have decided to work for something they can support," Politico reports.

8 Dec 2009

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension.

8 Dec 2009

Brazil: The largest emerging pharmaceutical market for hepatitis C virus

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that at approximately $120 million, the hepatitis C virus drug market in Brazil is among the largest emerging pharmaceutical markets for the disease.

8 Dec 2009

Three university academic groups sponsored for the MetaMiner project

GeneGo, Inc., the leading systems biology tools company, announced today that Millipore Corporation has sponsored academic groups from University of Queensland, Sheffield and USC to become members of the collaborative MetaMiner (Stem Cells) project run by GeneGo. MetaMiner is a partnership program for the reconstruction of stem cell pathways and their application in analysis of experimental data as well as knowledge mining.

8 Dec 2009

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.

8 Dec 2009

First Edition: December 8, 2009

Today's headlines highlight how Senate consideration of the health bill could become even messier with amendments pending on abortion funding restrictions and the reimportation of prescription drugs. All the while, Senate Dems continue to work to find common ground on the public option.

8 Dec 2009

New iPhone application to help find the top doctor

Have no fear during holiday travel this year — if you’re in a strange city, feel flu-like symptoms coming on and want to find a doctor, there’s a new iPhone App that will find one for you. The i Need a Doctor™ (www.ineedadoc.net) app is a joint venture between The Paladin Group LLC, the app developer, and two of the most respected doctor-rating services in the United States — the health care research organization Castle Connolly Medical Ltd. (www.castleconnolly.com) and the physician rating site DrScore (www.drscore.com).

8 Dec 2009

Eidogen-Sertanty licenses its TIP technology for FDA's National Center for Toxicological Research

Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, announced today they have licensed their Target Informatics Platform (TIP) to the U.S. Food and Drug Administration's National Center for Toxicological Research (NCTR).

8 Dec 2009

TLC Gift of Sight: A new financing option for corrective eye surgery

According to the Employee Benefits Research Institute, 30 million Americans use a Flexible Spending Account (FSA) to pay for qualified medical expenses, such as laser eye surgery.

8 Dec 2009

Consumer Watchdog: Opponents of health reform are fear-mongering relentlessly during Senate debate

Opponents of health reform are fear-mongering relentlessly during prolonged Senate debate, said Consumer Watchdog, spinning endlessly the lobbying messages of the insurance industry.

8 Dec 2009

BARDA cancels PharmAthene's RFP for Recombinant Protective Antigen Anthrax Vaccine

PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services Biomedical Research and Development Authority (BARDA) has canceled its request for proposal (RFP) for Recombinant Protective Antigen Anthrax Vaccine for the Strategic National Stockpile (RFP BARDA 08-15).

8 Dec 2009

New data provide comprehensive review of emerging role of small airways in asthma management

Teva Respiratory, a division of Teva Pharmaceutical Industries Ltd., today announced the publication of four articles in a special supplement of the December issue of the Journal of Allergy and Clinical Immunology (JACI), providing a comprehensive scientific review of the emerging role of the small airways in the understanding and treatment of asthma.

8 Dec 2009

$Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma$

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced results from an ongoing Phase 2 study, known as the 004 study, of the company's lead proteasome inhibitor, carfilzomib.

8 Dec 2009

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Sickle cell disease, a condition characterized by deformed and dysfunctional red blood cells, is one of the most common genetic blood disorders affecting millions of people around the world, including more than 70,000 Americans (National Heart, Lung, and Blood Institute.

8 Dec 2009

Erbitux gaining market share of Avastin in Europe

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.

8 Dec 2009

Tranzyme Pharma and Bristol-Myers Squibb sign collaboration agreement

Tranzyme Pharma today announced that it has entered into a strategic collaboration agreement with Bristol-Myers Squibb Company to discover, develop and commercialize novel macrocyclic compounds directed against targets of interest to Bristol-Myers Squibb.

8 Dec 2009

BIOGUARD barrier gauze dressings exhibit high antiviral efficacy against H1N1 virus

An independent lab report demonstrated that BIOGUARD™ barrier gauze dressings exhibit greater than 99.9% inactivation rates against swine flu virus after exposure for 24 hours.

8 Dec 2009

Catholics for Choice's statement on restriction of abortion coverage

"Today, Senator Ben Nelson (D-Nebraska) put the policy priorities of the U.S. Catholic bishops before the needs of women nationwide. Originally, Senator Nelson maintained that the abortion language in the healthcare bill was not a make-or-break factor in his vote.

8 Dec 2009

Opportunity for wireless technologies in Western Europe's e-healthcare market

Healthcare in Europe is facing major challenges in both structural reform and unavailability of resources as the region's working population is far lower in comparison to those of 'non-working' age. This calls for the introduction of new schemes in healthcare that would enable Europe to deal with issues pertaining to the growing ageing population.

8 Dec 2009

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in its Phase I/IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in combination with standard antiviral treatment and vaccination in HBeAg-negative chronic hepatitis B-infected (HBV) patients.

8 Dec 2009

Research News and Research

An unexpected ally for health reform: The restaurant industry

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Brazil: The largest emerging pharmaceutical market for hepatitis C virus

Three university academic groups sponsored for the MetaMiner project

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

First Edition: December 8, 2009

New iPhone application to help find the top doctor

Eidogen-Sertanty licenses its TIP technology for FDA's National Center for Toxicological Research

TLC Gift of Sight: A new financing option for corrective eye surgery

Consumer Watchdog: Opponents of health reform are fear-mongering relentlessly during Senate debate

BARDA cancels PharmAthene's RFP for Recombinant Protective Antigen Anthrax Vaccine

New data provide comprehensive review of emerging role of small airways in asthma management

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Erbitux gaining market share of Avastin in Europe

Tranzyme Pharma and Bristol-Myers Squibb sign collaboration agreement

BIOGUARD barrier gauze dressings exhibit high antiviral efficacy against H1N1 virus

Catholics for Choice's statement on restriction of abortion coverage

Opportunity for wireless technologies in Western Europe's e-healthcare market

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring